
    
      The protocol is a comparison of 2 strategies to prevent mother-to-child transmission of T.
      gondii following maternal seroconversion.

      Screening for toxoplasmosis is mandatory in France. Patients with confirmed seroconversion
      will be eligible for the trial, after 14 weeks gestational age.

      Participants will be randomly allocated to one of the treatment groups, and will receive
      open-label pyrimethamine + sulfadiazine or spiramycin.

      The protocol will not change the usual procedures for prenatal diagnosis, nor will it change
      the management of infected fetuses and neonates.
    
  